Free Trial
→ The case for $20,000 gold before year end (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.16
-4.1%		$1.12
$0.56
▼
$2.72
$119.94M1.612.59 million shs2.91 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$190.01
+0.6%		$125.46
$22.28
▼
$208.90
$75.86B1.0914.04 million shs10.27 million shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.72
+0.6%		$1.69
$1.30
▼
$3.48
$520M1.771.74 million shs1.09 million shs
YD Bio Limited stock logo
YDES
YD Bio
$8.11
+3.8%		$3.86
$1.70
▼
$22.00
$574.10M-1.55646,729 shs546,512 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%-1.69%-14.71%-4.92%-51.05%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-4.46%+27.63%+138.23%+588.44%
ProKidney Corp. stock logo
PROK
ProKidney
0.00%+7.50%-10.42%-15.27%-33.85%
YD Bio Limited stock logo
YDES
YD Bio
0.00%+41.54%+120.98%+326.84%+810,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.16
-4.1%		$1.12
$0.56
▼
$2.72
$119.94M1.612.59 million shs2.91 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$190.01
+0.6%		$125.46
$22.28
▼
$208.90
$75.86B1.0914.04 million shs10.27 million shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.72
+0.6%		$1.69
$1.30
▼
$3.48
$520M1.771.74 million shs1.09 million shs
YD Bio Limited stock logo
YDES
YD Bio
$8.11
+3.8%		$3.86
$1.70
▼
$22.00
$574.10M-1.55646,729 shs546,512 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%-1.69%-14.71%-4.92%-51.05%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-4.46%+27.63%+138.23%+588.44%
ProKidney Corp. stock logo
PROK
ProKidney
0.00%+7.50%-10.42%-15.27%-33.85%
YD Bio Limited stock logo
YDES
YD Bio
0.00%+41.54%+120.98%+326.84%+810,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.75
Moderate Buy$3.17172.99% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$77.83-59.04% Downside
ProKidney Corp. stock logo
PROK
ProKidney
2.67
Moderate Buy$12.00597.67% Upside
YD Bio Limited stock logo
YDES
YD Bio
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest INO, MRNA, YDES, and PROK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$60.00 ➝ $80.00
9/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/23/2026
Moderna, Inc. stock logo
MRNA
Moderna
Singular Research logo
Singular Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/22/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$40.00 ➝ $81.00
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
8/13/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$60K1,999.07N/AN/A$0.36 per share3.22
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B39.02N/AN/A$22.14 per share8.58
ProKidney Corp. stock logo
PROK
ProKidney
$890K584.26N/AN/A($3.36) per share-0.51
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$84.95M-$0.91N/AN/AN/AN/A-669.94%-73.97%11/10/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
ProKidney Corp. stock logo
PROK
ProKidney
-$68.99M-$0.55N/AN/AN/A-10,288.39%N/A-27.39%11/9/2026 (Estimated)
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest INO, MRNA, YDES, and PROK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/1/2026Q2 2026
YD Bio Limited stock logo
YDES
YD Bio
N/A$0.05N/A$0.0450N/A$0.42 million
8/12/2026Q2 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.2167-$0.07+$0.1467-$0.07$0.53 millionN/A
8/10/2026Q2 2026
ProKidney Corp. stock logo
PROK
ProKidney
-$0.14-$0.15-$0.01-$0.15$0.19 million$0.15 million
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
1.00
1.00
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
ProKidney Corp. stock logo
PROK
ProKidney
N/A
8.36
8.36
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%
YD Bio Limited stock logo
YDES
YD Bio
N/A

Insider Ownership

CompanyInsider Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.70%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
ProKidney Corp. stock logo
PROK
ProKidney
39.83%
YD Bio Limited stock logo
YDES
YD Bio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
112103.40 million101.64 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
ProKidney Corp. stock logo
PROK
ProKidney
231302.32 million181.91 millionOptionable
YD Bio Limited stock logo
YDES
YD Bio
1570.79 millionN/AN/A

Recent News About These Companies

Wall Street Zen Upgrades YD Bio (NASDAQ:YDES) to "Hold"
September 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31051451
Cours YD Bio Limited
September 24, 2026  |  zonebourse.comZ
YD Bio (NASDAQ:YDES) CEO Ethan Phd Shen Purchases 3,100 Shares of Stock
September 11, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ydes-insider-buying-and-selling-2026-09-11/
中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%
September 1, 2026  |  finet.hkF
YD Bio Ltd (YDES)
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/YDES/news/
YD Bio Files First-Half 2026 Results, Reports Improved Equity Position
September 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/yd-bio-files-first-half-2026-results-reports-improved-equity-position?utm_source=marketbeat.com&utm_medium=referral
YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million
August 31, 2026  |  quiverquant.comQ
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
August 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353740/0/en/yd-bio-limited-reports-unaudited-financial-results-for-the-six-months-ended-june-30-2026.html
YDES - YD Bio Limited
August 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/YDES/historical-price-quotes
Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan
August 26, 2026  |  zonebourse.comZ
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350403/0/en/yd-bio-announces-peer-reviewed-publication-in-nutrients-co-authored-with-physicians-from-the-taiwan-chronic-disease-healthcare-association-and-the-future-health-institute.html
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...
August 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/yd-bio-launches-a-physician-partnership-initiative-in-taiwan-with-the-announcement-of-two-nutraceutical-products-in-collaboration-with-the-taiwan-chronic-disease-healthcare-association-and-the-1036440665
YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem
August 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/yd-bio-launches-physician-led-nutraceuticals-in-taiwan-to-build-consumer-health-ecosystem?utm_source=marketbeat.com&utm_medium=referral
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
August 4, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/yd-bio-highlights-peer-reviewed-publication-on-new-computational-framework-for-keratoconus-research-1036405738
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
July 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/yd-bio-launches-cross-border-120000068.html
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
July 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/yd-bio-and-eg-biomed-conclude-successful-exhibition-at-bio-asia-taiwan-2026-highlighting-innovations-in-ophthalmology-oncology-diagnostics-and-clinical-services-1036356738
YD Bio Limited
July 15, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/YDES
YD Bio Limited Ordinary Shares (YDES) Insider Activity
July 14, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/ydes/insider-activity
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321265/0/en/yd-bio-expands-u-s-laboratory-footprint-to-46-states-strengthening-dna-methylation-early-cancer-detection-operations.html
YD Bio Ltd.
June 25, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/ydes/research-ratings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A fuel pump nozzle refuels a black car at a gas station under an overcast sky.
High Gas Prices Aren't Budging—Here Are 3 Stocks That Benefit
By Nathan Reiff | September 7, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
LNG tanker with rounded storage domes docked at a coastal terminal with large storage tanks and pipelines.
Running on Empty: 3 Energy Plays for Europe's Deep Freeze
By Jeffrey Neal Johnson | September 15, 2026
A gold-and-metal quantum computing cryostat with layered cooling stages, set against a blurred American flag backdrop.
Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
By Jeffrey Neal Johnson | September 10, 2026
Analyst reviewing printed charts and holding a pen at a desk with dual monitors displaying stock price and bar charts.
Analyst Rating Boosts May Signal More Upside for These 3 Stocks
By Nathan Reiff | September 28, 2026
Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.16 -0.05 (-4.13%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.17 +0.01 (+0.86%)
As of 10/2/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna stock logo

Moderna NASDAQ:MRNA

$190.01 +1.07 (+0.57%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$189.57 -0.44 (-0.23%)
As of 10/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

ProKidney stock logo

ProKidney NASDAQ:PROK

$1.72 +0.01 (+0.58%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.74 +0.02 (+0.87%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

YD Bio stock logo

YD Bio NASDAQ:YDES

$8.11 +0.30 (+3.84%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$7.99 -0.12 (-1.47%)
As of 10/2/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas